Proton Therapy for
Stage II-III Non-Small-Cell Lung Cancer
(NSCLC):
3 prospective, multicenter trials in the USA:
●Phase III Trial initiated by MGH/MDACC photons
versus protons to 74 Gy (completed accrual)
●Phase III RTOG trial photons versus protons to 70Gy or
lower as per strict OAR constraints (open)
●Phase II hypofractionated dose escalation trial 60 Gy at
25 Gy/frct up to 4 Gy/frct– Univ. Florida PTC (open for
accrual)